• Vaccine Ontology ID: VO_0011480
• Type: DNA vaccine
• Status: Research
• Antigen: Human papillomavirus E6
• E6 Type 16 gene engineering:
  • Type: DNA vaccine construction
  • Description: To generate pNGVL4a-E6, E6 was isolated from pcDNA3-E6 and cloned into pNGVL4a vector. To generate pNGVL4a-E6/opt, codonoptimized E6 synthesized by GenScript Corporation (Piscataway, NJ) was cloned into EcoRI/BamHI of pNGVL4a vector. The DNA and amino acid sequences of the wild-type E6 gene as well as the codon-optimized E6 were fully sequenced (Lin et al., 2006).
  • Detailed Gene Information: Click Here.
• Vector: pNGVL4a
• Immunization Route: Intradermal injection (i.d.)

Mouse Response

• Host Strain: C57BL/6
• Vaccination Protocol: Gold particles coated with pNGVL4a, pNGVL4a-E6 or pNGVL4a-E6/opt were delivered to the shaved abdominal regions of mice by using a helium-driven gene gun (Bio-Rad Laboratories Inc., Hercules, Calif.) with a discharge pressure of 400 lb/in^2. Mice were immunized with 2 lg of the DNA vaccine and received two boosts with the same dose at 1-week interval. Splenocytes were harvested 1 week after the last vaccination (Lin et al., 2006).
• Challenge Protocol: One week after the last vaccination, mice were challenged with 5 x10^4 TC-1 tumor cells mouse subcutaneously in the right leg and monitored once a week by inspection and palpation (Lin et al., 2006).
• Efficacy: C57BL/6 mice vaccinated with pNGVL4a-E6/opt are able to generate potent protective and therapeutic antitumor effects against challenge with E6-expressing tumor cell line, TC-1 of HPV (Lin et al., 2006).